This can be achieved by upregulating MHC I expression to directly modulate tumor immunogenicity and by enhancing the efficacy and quantity of CD8+ T cells through the enhanced interaction between endogenous-like B cells (ILBs) and effector helper T cells (TH cells) (Figure 3B). This evidence concerns the gene CD8A and neoplasm.